ScandiDos AB (publ) (SDOS.ST)
SEK 1.64
(-1.2%)
SEK 1.64
(-1.2%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 61.03 Million SEK | -8.91% |
| 2022 | 61.17 Million SEK | 10.32% |
| 2021 | 55.44 Million SEK | 5.77% |
| 2020 | 52.42 Million SEK | -9.3% |
| 2019 | 57.79 Million SEK | 4.45% |
| 2018 | 55.33 Million SEK | 8.84% |
| 2017 | 50.83 Million SEK | 1.33% |
| 2016 | 50.16 Million SEK | 23.56% |
| 2015 | 40.6 Million SEK | -7.31% |
| 2014 | 43.8 Million SEK | 19.36% |
| 2013 | 36.7 Million SEK | 9.61% |
| 2012 | 33.48 Million SEK | 32.19% |
| 2011 | 25.32 Million SEK | 15.56% |
| 2010 | 21.91 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 10.34 Million SEK | -43.55% |
| 2023 Q1 | 14.47 Million SEK | 6.71% |
| 2023 FY | 61.03 Million SEK | -0.22% |
| 2023 Q4 | 18.32 Million SEK | 35.09% |
| 2023 Q3 | 13.56 Million SEK | -9.54% |
| 2023 Q2 | 14.99 Million SEK | 3.56% |
| 2022 Q4 | 13.56 Million SEK | -13.88% |
| 2022 Q1 | 16.49 Million SEK | 8.73% |
| 2022 FY | 61.17 Million SEK | 10.32% |
| 2022 Q2 | 15.36 Million SEK | -6.89% |
| 2022 Q3 | 15.75 Million SEK | 2.55% |
| 2021 Q2 | 13.14 Million SEK | 2.68% |
| 2021 Q4 | 15.17 Million SEK | 5.84% |
| 2021 FY | 55.44 Million SEK | 5.77% |
| 2021 Q1 | 12.8 Million SEK | -12.23% |
| 2021 Q3 | 14.33 Million SEK | 9.06% |
| 2020 Q3 | 13.19 Million SEK | 6.65% |
| 2020 Q4 | 14.58 Million SEK | 10.54% |
| 2020 FY | 52.42 Million SEK | -9.3% |
| 2020 Q1 | 12.44 Million SEK | -2.55% |
| 2020 Q2 | 12.36 Million SEK | -0.61% |
| 2019 Q4 | 12.77 Million SEK | -21.14% |
| 2019 Q3 | 16.19 Million SEK | 11.57% |
| 2019 FY | 57.79 Million SEK | 4.45% |
| 2019 Q1 | 14.31 Million SEK | 34.02% |
| 2019 Q2 | 14.51 Million SEK | 1.4% |
| 2018 Q3 | 15.7 Million SEK | 18.53% |
| 2018 Q4 | 10.68 Million SEK | -31.99% |
| 2018 FY | 55.33 Million SEK | 8.84% |
| 2018 Q2 | 13.25 Million SEK | -15.58% |
| 2018 Q1 | 15.69 Million SEK | 24.04% |
| 2017 Q4 | 12.65 Million SEK | -0.57% |
| 2017 FY | 50.83 Million SEK | 1.33% |
| 2017 Q1 | 12.61 Million SEK | 11.92% |
| 2017 Q2 | 12.26 Million SEK | -2.78% |
| 2017 Q3 | 12.72 Million SEK | 3.73% |
| 2016 Q1 | 12.35 Million SEK | 9.38% |
| 2016 FY | 50.16 Million SEK | 23.56% |
| 2016 Q4 | 11.27 Million SEK | -15.62% |
| 2016 Q3 | 13.36 Million SEK | 7.25% |
| 2016 Q2 | 12.45 Million SEK | 0.87% |
| 2015 Q1 | 9.5 Million SEK | -22.33% |
| 2015 Q4 | 11.29 Million SEK | 12.79% |
| 2015 Q2 | 9.64 Million SEK | 1.55% |
| 2015 Q3 | 10.01 Million SEK | 3.77% |
| 2015 FY | 40.6 Million SEK | -7.31% |
| 2014 FY | 43.8 Million SEK | 19.36% |
| 2014 Q4 | 12.23 Million SEK | 17.59% |
| 2014 Q2 | 11.13 Million SEK | 11.0% |
| 2014 Q1 | 10.03 Million SEK | -0.61% |
| 2014 Q3 | 10.4 Million SEK | -6.6% |
| 2013 Q4 | 10.09 Million SEK | 14.03% |
| 2013 FY | 36.7 Million SEK | 9.61% |
| 2013 Q1 | 8.46 Million SEK | -16.13% |
| 2013 Q2 | 9.28 Million SEK | 9.69% |
| 2013 Q3 | 8.85 Million SEK | -4.66% |
| 2012 Q4 | 10.09 Million SEK | 21.13% |
| 2012 Q3 | 8.33 Million SEK | 0.0% |
| 2012 FY | 33.48 Million SEK | 32.19% |
| 2011 FY | 25.32 Million SEK | 15.56% |
| 2010 FY | 21.91 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | 26.327% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 90.023% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 90.023% |
| Arcoma AB | 53.25 Million SEK | -14.621% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -1128.376% |
| BICO Group AB (publ) | 2.84 Billion SEK | 97.857% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 70.996% |
| CellaVision AB (publ) | 295.99 Million SEK | 79.378% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | 11.449% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -4562.297% |
| C-Rad AB (publ) | 3.8 Million SEK | -1506.263% |
| Duearity AB (publ) | 21.58 Million SEK | -182.78% |
| Dignitana AB (publ) | 74.73 Million SEK | 18.329% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -2160.667% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.433% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -234.848% |
| Iconovo AB (publ) | 63.35 Million SEK | 3.656% |
| Integrum AB (publ) | 90.57 Million SEK | 32.608% |
| Luxbright AB (publ) | 23.09 Million SEK | -164.342% |
| Mentice AB (publ) | 237.06 Million SEK | 74.252% |
| OssDsign AB (publ) | 175.6 Million SEK | 65.241% |
| Paxman AB (publ) | 133.8 Million SEK | 54.381% |
| Promimic AB (publ) | 48.55 Million SEK | -25.717% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 62.412% |
| SciBase Holding AB (publ) | 69.97 Million SEK | 12.773% |
| Sectra AB (publ) | 39.06 Million SEK | -56.255% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 65.027% |
| Senzime AB (publ) | 141.51 Million SEK | 56.869% |
| SpectraCure AB (publ) | 12.12 Million SEK | -403.282% |
| Stille AB | 87.21 Million SEK | 30.018% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 98.904% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 86.157% |